Last reviewed · How we verify
NCT01778491
AMD Phenotype and Genotype Study
trial in Age-Related Macular Degeneration in 344 participants. Completed in 29 September 2015.
29 September 2015
Quick facts
| Lead sponsor | National Eye Institute (NEI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 344 |
| Start date | 5 November 2012 |
| Primary completion | 29 September 2015 |
| Estimated completion | 29 September 2015 |
| Sites | 2 locations across United States, Germany |
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
- AMD — all drugs for AMD →
Sponsor
National Eye Institute (NEI)
Who can join
Adults 60 to 90, any sex, with Age-Related Macular Degeneration or AMD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- Age-related macular degeneration (AMD) is a disease that blurs the sharp vision needed for activities such as reading, sewing, and driving. It affects the macula, the center of the retina at the back of the eye, which allows a person to see fine detail. Researchers want to collect medical histories, eye exam data, and genetic information that may be associated with AMD. They want to compare this information with information collected from people without AMD. Objectives: \- To collect medical information and gene samples for researchers studying AMD. Eligibility: * Individuals between and 60 and 90 years of age who have AMD in at least one eye. * Individuals between and 60 and 90 years of age who have no AMD in either eye. Design: * This study will involve one study visit. This study visit will last 6 to 8 hours. * Participants will have the following tests and exams as part of their study visit: * Full physical exam and medical history * Full eye examination * Laser scan of the eye * Retina function test * Vision sensitivity test * Optional blood sample (for genetic study) * No treatment will be provided as part of this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01778491
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
Other National Eye Institute (NEI) trials
Trials by the same sponsor.
- NCT06491615 — National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and · recruiting
- NCT04289571 — Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease · Phase 1 · recruiting
- NCT04833361 — Potential Environmental Causes of Uveal Coloboma · completed
- NCT06670989 — Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss · NA · active not recruiting
- NCT04591483 — Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01778491 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Eye Institute (NEI)
- Last refreshed: 5 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01778491.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing